Akari Therapeutics Plc (AKTX) stock
AKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$5.70−0.81 (-12.44%)
Close on Nov 17, 2026Market cap $11.10MP/E –Yield –
Akari Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Akari Therapeutics's ebitda for the twelve months ending Dec 31, 2024 was -$21.63M. For fiscal 2024 it was -$21.63M. The highest annual figure on record is -$1.91M in fiscal 2014.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$21.63M | – |
| FY2023 | Dec 31, 2023 | -$16.80M | – |
| FY2022 | Dec 31, 2022 | -$23.08M | – |
| FY2021 | Dec 31, 2021 | -$17.21M | – |
| FY2020 | Dec 31, 2020 | -$17.97M | – |
| FY2019 | Dec 31, 2019 | -$16.94M | – |
| FY2018 | Dec 31, 2018 | -$20.75M | – |
| FY2017 | Dec 31, 2017 | -$37.74M | – |
| FY2016 | Dec 31, 2016 | -$27.21M | – |
| FY2015 | Dec 31, 2015 | -$30.57M | – |
| FY2014 | Dec 31, 2014 | -$1.91M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | -$5.28M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.93M | – |
| Q2 FY2024 | Jun 30, 2024 | -$7.45M | – |
| Q1 FY2024 | Mar 31, 2024 | -$5.98M | – |
| Q4 FY2023 | Dec 31, 2023 | -$5.09M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.51M | – |
| Q2 FY2023 | Jun 30, 2023 | -$4.61M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.59M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.89M | – |
| Q3 FY2020 | Sep 30, 2020 | -$245.90K | – |
| Q2 FY2020 | Jun 30, 2020 | -$5.91M | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.92M | -28187.0% |
| Q4 FY2019 | Dec 31, 2019 | -$7.82M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.11M | – |
| Q2 FY2019 | Jun 30, 2019 | -$6.03M | – |
| Q1 FY2019 | Mar 31, 2019 | $17.53K | – |
See a number that looks wrong?